Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Satellos Bioscience Inc., a regenerative medicine company that spun out of Stem Cell Network, recently announced that it has closed $55 million financing to support the development of its lead drug candidate for Duchenne muscular dystrophy with the potential to significantly change the prospects for improved quality of life for patients.

Satellos presented at the OBIO® Investment Summit and is a CAAP® alumnus.

Arsheen Kaur
Previous

Pfizer Canada Launches National Initiative to Propel Startup Solutions for Key Challenges in Healthcare
Next

CATTI opens a cell and gene therapy training centre of excellence at the University of Guelph